In an unprecedented advancement in drug discovery, Zapata Computing, Inc., alongside Insilico Medicine, the University of Toronto, and St. Jude Children’s Research Hospital, has showcased the remarkable potential of quantum-enhanced generative AI. This collaboration has led to the first-ever instance where a generative model operating on quantum hardware surpasses traditional classical models in generating viable cancer drug candidates.
This landmark study focused on developing novel KRAS inhibitors, a notoriously difficult target in cancer therapy. Utilizing advanced generative AI models on both classical and quantum hardware, including a 16-qubit IBM device, the team successfully generated one million drug candidates. Following a meticulous process of algorithmic and human filtering, the quantum-enhanced generative model yielded two distinct molecules with superior binding affinity over those produced by classical models. This breakthrough not only underlines the efficacy of quantum computing in drug discovery but also illustrates the transformative role of Industrial Generative AI in addressing complex, domain-specific challenges in various industries.
Industrial Generative AI, a specialized subcategory of generative AI, is particularly adept at tackling such intricate problems. Unlike general-purpose AI tools like ChatGPT and DALL-E from OpenAI, Industrial Generative AI is customized to address specific issues within enterprises or industries. It navigates through challenges such as data disarray, large solution spaces, unpredictability, time sensitivity, compute constraints, and demands for accuracy, reliability, and security. At its core are generative models, like Large Language Models (LLMs), which learn from training data to generate new, realistic outputs. This approach is what enabled the Zapata AI team to pioneer in the field of drug discovery, leveraging AI to create groundbreaking solutions.
Yudong Cao, CTO and co-founder of Zapata AI, highlighted the synergy of quantum and classical computing in providing comprehensive solutions in this groundbreaking project. The research, currently awaiting peer review and available on ArXiv, builds on earlier studies demonstrating the potential of quantum generative AI in drug discovery.
Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Medicine, acknowledged the integration of Insilico’s generative AI engine, Chemistry42, with quantum-augmented models, heralding new therapeutic avenues for challenging cancer targets. This step is critical in advancing the future of drug discovery.
With a recent strategic partnership with D-Wave Quantum Inc., Zapata AI is set to further expand the horizons of quantum generative AI models in discovering new molecules for a range of commercial applications. Christopher Savoie, CEO and co-founder of Zapata AI, expressed excitement about this development and the potential for broader application in various industries.
Alán Aspuru-Guzik, a professor at the University of Toronto and a co-founder and Scientific Advisor of Zapata AI, shared his optimism about integrating quantum computing into the drug discovery pipeline. This research is pioneering, setting a precedent for future quantum computers to showcase their unique capabilities.
The research employed Zapata AI’s QML Suite Python Package, available on its Orquestra® platform, emphasizing the practical application of quantum computing in solving real-world scientific challenges. This integration of Industrial Generative AI into the drug discovery process marks a significant stride in leveraging AI for innovative, industry-specific solutions, driving growth and efficiency in the ever-evolving technological landscape.
Credit: Source link
